Home

CSL Limited

ASX Code

CSL

Sector

Pharmaceuticals- Biotechnology & Life Sciences

Investor Centre

https://www.csl.com/investors

Website

https://www.csl.com/

About

Over a century ago in Melbourne, Australia, we made a promise to save lives and protect the health of people who were stricken with a range of serious and chronic medical conditions. Today, as a leading global biotech company, that same promise has never been stronger. We develop and deliver innovative biotherapies and influenza vaccines that save lives, and help people with life-threatening medical conditions live full lives. We are driven by our deep passion to serve hundreds of thousands of patients and other stakeholders around the world.

News

Deep dive into CSL, NUF & IPH and charts on China risks
Heated audience at CSL's AGM
Shareholders to receive more from CSL as revenue and earnings surge
Sonic Healthcare (ASX:SHL) expands presence in Switzerland
Market Smells Blood, Gives CSL a Whack
Bourse Discourse: CSL, EDV
Flu Division Helps Immunise CSL's Bottom Line
CSL - Macquarie rates the stock as Outperform
CSL - Macquarie rates the stock as Outperform
CSL - Morgan Stanley rates the stock as Overweight
CSL - Morgan Stanley rates the stock as Overweight
CSL - Morgans rates the stock as Add
CSL Shares Rally Strongly Despite Earnings Dip
CSL - Morgan Stanley rates the stock as Equal-weight
CSL - Morgans rates the stock as Add
CSL Confirms Vifor Talks
CSL - Morgan Stanley rates the stock as Equal-weight
CSL - Morgan Stanley rates the stock as Equal-weight
CSL - Morgans rates the stock as Add
Profit Briefs: CSL, AMC
CSL - Citi rates the stock as Downgrade to Neutral
CSL - Macquarie rates the stock as Outperform
CSL - Macquarie rates the stock as Neutral
CSL - Morgans rates the stock as Upgrade to Add
CSL - UBS rates the stock as Buy
CSL - Citi rates the stock as Neutral
ASX Poised For Weak Open As CSL Dumps Vaccine Trial
CSL - Macquarie rates the stock as Neutral
Canberra Provides CSL With New Vaccine Boost
CSL - Macquarie rates the stock as Neutral
CSL - UBS rates the stock as Buy
CSL - UBS rates the stock as Buy
CSL Tightens Guidance As Investors Zone In On Vaccine Boost
CSL Seals UQ Covid Vaccine Production Deal
CSL - Macquarie rates the stock as Neutral
CSL - Credit Suisse rates the stock as Outperform
Spotlight On CSL Revenue Targets
CSL Delivers Again With Higher Profit, Increased Dividend